Creators of TissueSpan,
a unique mesh, enabling the body to attract and organise its own cells for seamless tissue regeneration.
The team at Regenosca are creating the future for natural, regenerative surgical interventions with a wide range of potential applications.
Eva-Maria is a MedTech leader, with a PhD in Life Sciences from the École Polytechnique Fédérale de Lausanne (EPFL). She has the natural ability to cultivate motivated, high-performing teams, driving them to achieve their objectives. Her background blends scientific rigor with business and strategic leadership, supported by an Executive MBA.
Mattias is a seasoned regulatory consultant and bioengineer with a robust background in medical device regulation. He brings over six years of experience in this field, underpinned by more than a decade of scientific research in tissue engineering. Mattias earned his PhD in Life Sciences from EPFL and is recognized for his deep expertise in navigating the complex landscape of medical regulations.
Ganesh is a distinguished pediatric urologist with a strong research background and a passion for innovation. He practices at the renowned Great Ormond Street Hospital in London, with previous experience at the University of Malaya Medical Center. Ganesh’s extensive clinical network includes international thought leaders in reconstructive urology, reflecting his significant influence in the field.
A former medical doctor who trained MBChB in Edinburgh with interests in technology from an early age, Aydin has worked the past 3 decades as founder, entrepreneur, board director and advisor in industries from medtech through to business services, the internet and datacenter markets.
Dealing with soft tissue repair or replacement currently relies on synthetic and biological grafts or the patient donating their own tissue - approaches that face significant challenges, including donor dependency, rejection risk, and scarring.
We have created a unique implant, enabling the body to heal itself. Designed to reinforce or replace damaged tissue, the implant restores normal function and seamlessly integrates into the body, ultimately absorbing to leave only the patient’s own healed tissue.
Whilst there are a large number of possible applications, our initial target market is urethral stricture (narrowing) which affects up to a million patients a year in the US. The current gold-standard procedure involves open surgery and the harvesting of a patient's own inner mouth tissue for grafting. Simpler endoscopic treatments have up to 80% failure rates.
Regenosca has already performed in-vitro, animal, and human trials with excellent success and perfect regrowth of the patients’ own tissue.
News ItemRegenosca announces completion of First‑in‑Human clinical trial Lausanne, Switzerland – December 1, 2025 Regenosca is proud to announce the successful...
News ItemRegenosca launches the STAMP Project to advance manufacturing of TissueSpan Lausanne, Switzerland – September 12, 2025 - Regenosca is pleased...
News ItemRegenosca publishes new preclinical research supporting TissueSpan Lausanne, Switzerland – February 12, 2025 - Regenosca is pleased to announce the...
News ItemRegenosca is accepted into the SFITS Accelerator Program Lausanne, Switzerland – January 30, 2025 - Regenosca is proud to announce...
News ItemRegenosca closes CHF 1 million pre-seed round to demonstrate endoscopic delivery of TissueSpan implants. Lausanne, Switzerland - July 22, 2024...
News ItemAydin Kurt-Elli was appointed as a new board member of Regenosca SA. His experience as an entrepreneur, his knowledge in...
Regenosca SA
Avenue de Sevelin 13C
1004 Lausanne